Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. - Test2 - elhamkhani - TriplyDB

Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update.

Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update.

http://www.wikidata.org/entity/Q38210319

about

Vaccination against respiratory Pseudomonas aeruginosa infection Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.Precision medicine for the treatment of severe pneumonia in intensive care.Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines.What if there were no new antibiotics? A look at alternatives.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.PA0833 Is an OmpA C-Like Protein That Confers Protection Against Pseudomonas aeruginosa Infection.

P2860

Q26824014-2BA6EE3E-F48B-4A5F-A2B9-B2C8C863D368 Q33822579-3451F1A5-CE4F-4CAF-8BAD-BE587AB05E32 Q38704065-ECE8BFAF-CEA9-4524-9DE2-8BBE483E7179 Q38807834-7D1DA18F-21AF-4147-AAC4-6E970458A558 Q38966367-FFB29ABB-0861-4F70-BDBE-7D6A8F0C1C3A Q40095692-677E852D-69F3-4F27-B0E5-5BBA769DD508 Q40267074-AD7B0778-44CF-446A-9D0E-DC0B81ECBDF5 Q40591899-26E27B05-DE89-49E6-9ED1-7ADD1CF4ED97 Q55222812-AF0F68C2-BE7F-4A35-B6D5-6BCD92AFADF0

P2860

Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update.

http://www.wikidata.org/entity/Q38210319

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Vaccine development and passiv ...... l patients: a clinical update.

@en

type

label

Vaccine development and passiv ...... l patients: a clinical update.

@en

prefLabel

Vaccine development and passiv ...... l patients: a clinical update.

@en

P1433

Q38210319-B48B3DC6-F63E-4724-951F-DC9C2EE9E455

P1476

Q38210319-47610ED9-47DF-4F97-B08C-16B8B6F8A953

P2860

Q38210319-007ABCCF-3E66-4660-8CD9-C9E27396BD15

Q38210319-066E5490-D8A9-47DC-B377-37F0877D649F

Q38210319-06DCBAB3-1C36-40C8-9216-7F7495061D48

Q38210319-0AF61814-11BC-436F-B56C-0CA3EEBABA25

Q38210319-0DE2011D-9FC2-49EE-9E47-CB866E03DFAA

Q38210319-0FF575B4-8AE3-464A-BB30-BB0F28151BBE

Q38210319-1096A3AE-5459-4977-B2B3-90A64788453E

Q38210319-1A3DC352-EAB6-40BB-BFA3-81FA7CD4F23A

Q38210319-1FE3A769-68FB-4176-8EC6-94CABF527ECD

Q38210319-248F08E2-8EC7-489B-A7E8-E70B955BEE8E

P304

Q38210319-58E88F28-45C0-4D5A-AFA1-EF79C8CCFA7F

P31

Q38210319-D6A27DC2-A5EA-4105-BE92-3BA0EBCB8AB9

P356

Q38210319-554CDEC7-7E31-4FE3-BE20-7AE9D862F799

P433

Q38210319-A1DC6131-7B03-4881-B84B-7E82275C443C

P478

Q38210319-501602EB-D67E-4B9A-9465-E893888E128B

P50

Q38210319-E37F9C8F-D4FC-4E54-BB98-44DFD232BA58

P577

Q38210319-2A7F8530-40E0-4207-BED8-33F54A7BCB84

P698

Q38210319-5FF7F090-E2C8-4E77-BAD2-DE87B3CD817F

P921

Q38210319-01AB381F-7B9C-41B7-B11A-53CC3D8FD118

Q38210319-293FB77D-ABBD-4ACB-BBCD-5B7E66D96998

P356

P1433

Future Microbiology

P1476

Vaccine development and passiv ...... l patients: a clinical update.

@en

P2860

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

Vaccines and immunotherapy against Pseudomonas aeruginosa

Full virulence of Pseudomonas aeruginosa requires OprF

The epidemiology of sepsis in the United States from 1979 through 2000

Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.

Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5.

The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A.

Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients.

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Quorum-sensing genes in Pseudomonas aeruginosa biofilms: their role and expression patterns.

P304

457-463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FMB.14.10

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Louis Vincent

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24810345

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa